

PLANETS CANCER CHARITY

England & Wales · Charity number 1175572

Details

Status Registered

Legal form CIO

Registered 2017-11-06

Register [View on the Charity Commission register](#)

Contact

Address Milestone Cottage 113 Havant Road
Emsworth
Hampshire
PO10 7LG

Phone 07793451729

Email contact@planetscharity.org

Website www.planetscharity.org

Activities

Objects: 1. TO ADVANCE THE EDUCATION OF THE GENERAL PUBLIC (INCLUDING RELEVANT MEDICAL AND SCIENTIFIC COMMUNITIES) IN ALL AREAS RELATING TO ABDOMINAL CANCER INCLUDING PANCREATIC, LIVER, NEURO-ENDOCRINE, AND GASTROINTESTINAL TUMOURS. 2. TO PROMOTE THE PHYSICAL AND MENTAL HEALTH OF THOSE AFFECTED BY ABDOMINAL TUMOURS, THROUGH THE PROVISION OF SUPPORT, ADVICE AND EDUCATION TO PATIENTS, THEIR CARERS AND FAMILY MEMBERS.

Activities: PLANETS helps patients with pancreatic, liver, colorectal, abdominal and neuroendocrine cancer by funding patient support groups, innovative treatments and research.

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Other Defined Groups

Geography

- Bournemouth
- Devon
- Dorset
- Hampshire
- Isle Of Wight
- Portsmouth City
- Southampton City
- Surrey
- West Sussex
- Wiltshire

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£378,022	£242,753	-	-
2024-03-31	£419,896	£236,764	-	-
2023-03-31	£173,603	£208,621	-	-
2022-03-31	£468,232	£319,235	-	-
2021-03-31	£135,288	£185,099	-	-

Trustees

Name	Role	Appointed
NEIL WILLIAM PEARCE	Chair	2018-04-18
ALEX MIRNEZAMI		2018-04-18
BRIAN STEDMAN		2018-04-18
Caroline Marshall		2025-10-01
Dr Carol Davis		2025-10-01
Fergus Noble		2024-03-01
RUTH MARION HEIDI WILLRICH		2018-04-18
VICTORIA CAINE		2018-04-18

PLANETS CANCER CHARITY

England & Wales - Charity number 1175572

Accounts



REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their report with the financial statements of the charity for the year ended 31 March 2025 and have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

About PLANETS

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just over £2.5 million.

PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex.

Vision

Transforming cancer care in the south through our 'family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community.

Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other's contributions and work together with a shared vision. In line with our vision and objectives, we will ensure that:

- Patients and their families receive outstanding support
- The charity continues to support the provision of cutting-edge clinical care and treatment through investment in advanced and innovative treatments
- We consider our donors and beneficiaries in everything we do
- We are accountable for how we spend our income and the impact it makes
- We strive for continuous development and improvement of our team and the support and experience we provide
- We help drive a change in attitudes amongst health care professionals and the public to generate optimism around PLANETS cancers and their treatment

Our goals

- 1) Improve patient outcomes: Longer survival and a better quality of life through early diagnosis and enhanced treatment conditions.
- 2) Better patient experience: Improved support, information communication and facilities for patients.
- 3) Assist the development of our centres: We can only achieve goals 1 and 2 by facilitating the development of our clinical teams and centres, so we can attract funding for clinical support, diagnosis, therapeutics and research.

Objectives and activities

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments, and research.

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities. The trustees refer to public benefit throughout this report.

ACHIEVEMENT AND PERFORMANCE - Charitable activities

Since our inception in 2011, PLANETS Cancer Charity has grown from a hospital charity fund into a fully independent organisation in 2019. Over the past 14 years, we've built a powerful and supportive community of patients, carers and healthcare professionals. Together, we've achieved more than many thought possible.

Our Key Achievements Include:

- **Building a Supportive Network**
We have established a network of patient support groups and hosted educational conferences across the Wessex region, focusing on pancreatic, colorectal, oesophageal, and neuroendocrine cancers.
- **Pioneering Intra-Operative Radiotherapy (IORT)**
We successfully fundraised £1 million to introduce the UK's first mobile electron beam radiotherapy machine. This revolutionary technology delivers radiotherapy during surgery to treat advanced cancers. It has already treated over 200 patients (as of December 2022) and is expected to benefit more than 2,000 over its lifespan. The treatment has significantly reduced recurrence rates and led to groundbreaking clinical outcomes published in top international medical journals.

- **Advancing Cancer Research**

We have funded full-time PhD and MD researchers in pancreatic and neuroendocrine tumours to work with clinician-scientists at the globally renowned Cancer Immunology Centre at the University of Southampton.

- **Achieving Centre of Excellence Status**

In 2016, we helped the Southampton, Portsmouth and Bournemouth/Poole region attain European Neuroendocrine Cancer Centre of Excellence status, reflecting world-class standards in patient care and clinical research.

- **Supporting Innovative Treatments**

We funded the introduction of **Hyperthermic Intraperitoneal Chemotherapy (HIPEC)** at University Hospital Southampton—one of the UK’s first centres to offer this treatment, used to target cancers that have spread within the abdomen.

- **Employing a Dedicated Neuroendocrine Tumour Dietitian**


We funded one of the UK’s first full-time specialist dietitians focused solely on neuroendocrine tumour patients, helping manage the significant digestive complications associated with these rare cancers. This Dietitian was reappointed through Direct Hospitals after 2 years and now works permanently across the Dorset and Hampshire region.

- **Revolutionising Surgical Planning with 3D Printing**

We funded a trial using 3D-printed liver models based on individual patients’ CT scans. These personalised, anatomically precise models enable surgeons to better plan complex operations by visualising tumours and their proximity to vital structures. This innovation made Southampton the first UK centre to use this technology for liver cancer surgery—an initiative that garnered national media attention.

- **Improving Outcomes in Hilar Cholangiocarcinoma Surgery**

By converting CT and MRI scans into 3D models, we’re supporting better preoperative planning for hilar cholangiocarcinoma, a bile duct cancer often deemed inoperable until exploratory surgery. These models allow surgeons to assess critical structures ahead of time, reducing the risk of irreversible surgical decisions and improving patient outcomes.



- **Creating a Dedicated Wellbeing Room for Liver Patients**

We funded the complete refurbishment of a new wellbeing room on Ward D9 at University Hospital Southampton. The space offers patients a calm environment for rest and private conversations, away from the clinical setting.

PLANETS contributed £12,000 towards the facility, which was made possible through a partnership with Taylor Wimpey Southern Counties—our 2023 Charity of the Year—which raised over £20,000.



- **Funding the REMACS Study**

We supported the **Reconstruction in Extended Margin Cancer Surgery (REMACS)** study, which investigates patient quality of life and cost-effectiveness following perineal reconstruction in abdominopelvic cancer cases.

- **Supporting a Wide Range of Small but Vital Projects**

We continue to invest in numerous smaller initiatives that make a big difference to patient care. These include:

- Ultrasound machines and radioisotope delivery equipment
- DAB radios for radiotherapy bunkers
- Psychotherapy sessions for patients struggling with a cancer diagnosis
- Personalised fitness programmes to support cancer recovery

Each of these projects, large or small, reflects our mission: to improve outcomes and enhance the experience of patients facing pancreatic, liver, colorectal, oesophageal, and neuroendocrine cancers.

This year, we proudly funded the following impactful projects:

- **Advancing Early Detection of Pancreatic Cancer**

We are supporting ongoing research into pancreatic cancer-associated diabetes, genetic variants, and metabolomic analysis using the UK Biobank cohort. This work aims to develop effective strategies for the early detection of pancreatic cancer—widely regarded as having the poorest survival outcomes among all cancers.

- **Acquisition of a Robotic Ultrasound Probe for the UHS HPB Team**

Ultrasound plays a critical role in hepatopancreatobiliary (HPB) surgery, and its importance is magnified in robotic procedures where tactile feedback is absent. It is essential for mapping lesion margins, assessing proximity to major vascular structures, evaluating liver blood flow, and detecting occult disease.

Unlike traditional laparoscopic ultrasound, robotic ultrasound enables the console surgeon to maintain full control—crucial for precision and patient safety. While UHS has already invested in one robotic HPB ultrasound probe, a second was urgently needed to support multiple cases on the same operating list, as current sterilisation turnaround times are insufficient. With the HPB robotic surgery service set to expand significantly over the next 12–24 months, this investment was both timely and strategic.

- **Cancer Coaching sessions** - This year, we were delighted to welcome Alison Bailey, Cancer Coach, to the PLANETS team. Her addition enhances the emotional and practical support we offer to patients and their families. Cancer coaching provides a safe, supportive space for individuals to talk through their current experiences and challenges, while equipping them with tools to set realistic, achievable life goals. These sessions empower people to regain a sense of control during an otherwise uncertain time. The coaching is entirely person-centred and tailored to the specific needs of each participant, ensuring meaningful and individualised support.

- **Improving Postoperative Recovery with Valley Cushions**

Following pelvic exenteration surgeries, patients with perineal wounds currently rely on makeshift support such as two pillows, typically introduced around day 10 post-operation. However, this solution often lacks stability and can increase the risk of wound breakdown—an outcome affecting up to 25% of patients, with significant implications for recovery time and morbidity. The Valley Cushion is purpose-designed to redistribute weight and offload pressure from the perineal area, thereby enhancing comfort and reducing the likelihood of wound complications.

- **Equipping Surgical Teams with New Theatre Caps**

We have provided new theatre caps to ensure our surgical teams maintain high hygiene standards while benefiting from increased comfort during procedures and improve communication pressured operating theatre settings where new members of the team may not remember everybody's name/role immediately.

- **Supporting Medical Training**

We continue to contribute towards the education and development of healthcare professionals through dedicated funding for medical training initiatives.

All of this has brought our local cancer community together.

In line with our charitable goals, all funds we raise are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

Year in review – April 2024 to 31 March 2025

The last year has been one of consolidation, where we have been able to establish our funding priorities for the coming years by assessing a range of new projects and reevaluate our fundraising goals, in light of this. Although the overall fundraising climate remains challenging for UK charities due to national and international economic pressures, we have nonetheless been able to exceed our fundraising targets yet again. This has come about through a combination of individual donations and grants, fundraising events and successful grant applications. All of these have been very productive areas which have reflected positively on the success of our new staffing structure.

As a result, our balance sheet remains very healthy although we have significant ring-fenced funds for our new projects. We expect that over the next two years our reserve funds will probably reduce as we service these projects. Looking forward the prospects for the economic climate do not look good so we will need to prioritise grant applications and consider how best this may be achieved to ensure that we can continue to service our funding commitments.

Fundraising highlights have included our Dawn to Dusk cycle ride which raised over £66,000 and saw more than 50 riders of all levels of experience cycle from Winchester Cathedral to the Bristol Channel during the day. Our annual ball was held at the Grand in Southampton and was its usual success thanks to the extreme generosity of some of our auction prize donors. We have also had multiple small events including another tandem skydive, The Southsea Alternative Choir music gigs and a golf day.

We have been able to fund sessions from a cancer coach over the course of the year partly through successful grant applications. This is a new role which we will be evaluating to assess its long term value, in providing a different type of support for people living with cancer and their close relatives. In general the goal is to help individuals who are struggling with managing the diagnosis come to terms with it and find ways of developing coping strategies. These in turn enable them to feel more in control of their lives and as a result more able to balance the competing pressures that they face and live more rewarding and fruitful lives. The initial feedback is extremely positive and we are looking to continue this over the coming year.

Our Cancer Research projects continue to be productive, in particular we are looking to continue funding projects originally initiated by Liver and Pancreas Research and Development Fund also known as LAP R&D. This fund was transferred from Southampton Hospital Charity to PLANETS Cancer charity by mutual agreement in order to continue this project after the LAP R&D Fund founder, my former colleague Professor Mohammed Abu Hilal, moved abroad to work. At present this project is looking at data from the UK National Biobank to look for markers predicting development of pancreatic cancer. Early results are encouraging and we look forward to hearing more from this team.

Other areas of Cancer Research that we have continued to fund include evaluation of pelvic floor reconstruction following surgery for advanced cancers low in the pelvis. These results have been presented and published during this year and will help guide surgeons in future. A new area that we

have started to collaborate on is early research into a new group of potential chemotherapy agents which will work by attacking the mechanisms which allow cancer cells to spread. Normally chemotherapy works by interfering with the way tumour cells grow causing them to slow down or die.

The novel approach that we are exploring could have many applications including pancreatic, bowel and neuroendocrine cancers.

Our patient support groups have continued to expand into new areas, with the introduction of the first support group in the UK for patients recovering from complex pelvic floor surgery. This was very well attended by patients from across the country as well as those treated locally by our team of experts, led by PLANETS Trustee Professor Alex Mirnezami.

Over the course of the year one of our valued trustees Emily Medway asked to stand down and was replaced by Fergus Noble. I am extremely grateful to both for their commitment, help and service. Over the coming year we will look to further refresh and strengthen our Board of Trustees in order to continue to vigorously support our charitable objectives.

As always I am extremely grateful to our staff, trustees, patron, ambassadors and many supporters who continue to enable our charity to put the icing on the cake and maintain the strength of cancer care provision, patient support and research within the central South Coast area.

Neil Pearce - July 2025



Media Activity - April 2024 to April 2025

Over the course of this period, we recorded 190 items of coverage with an audience reach of 120 to 150 million impressions across national, regional and syndicated (news wire) media coverage.



Some of the stories which we have published in the media this year include:

May 2024

PLANETS hailed the decision to make an innovative and targeted radiotherapy treatment available on the NHS for patients with neuroendocrine tumours (NETs) in the liver.

We ran a press release urgently requesting a change in NHS commissioning that would allow patients equal access to Selective Internal Radiation Therapy (SIRT) for neuroendocrine tumours (NETs) that have spread to the liver.

It is currently only funded for NHS patients with primary liver cancer and colorectal cancer which has spread to the liver – despite the recent publication of NICE guidance which recommends SIRT as a standard treatment option for NET patients.

Funding this treatment would significantly improve outcomes for our patients and enhance the quality of care available across the UK.

June 2024

In June we raised an incredible £66,000 + at our 'Dawn to Dusk' cycle challenge - £10,000 over target.

Jo Green, director of operations and marketing for PLANETS who is a neuroendocrine cancer patient and participated in the 100-mile challenge, said: "We are immensely proud of what our patients, clinicians, supporters and sponsors achieved through our Dawn to Dusk challenge and cannot thank everyone enough – it truly was epic.

"We had a total of 54 participants aged from 15 to 74 who all made it through the 100 miles and who all played their part in securing £60,000 for the charity which will prove vital to the work we do for cancer patients.

“We all feel extremely fortunate to have shared this amazing experience with so many brilliant people and it really shows what can be achieved when people come together, not just in terms of fundraising but also the friendships and bonds created along the way.”



July 2024

PLANETS called on the government to intervene urgently over the shortage of a drug that can prevent life-threatening digestive problems in thousands of people with a range of medical conditions..

The treatment is often referred to as Creon which is the brand name of a commonly-used type of the drug. PERT is prescribed for patients with pancreatic deficiencies caused by a variety of conditions including pancreatic cancer, pancreatic surgery, cystic fibrosis, chronic pancreatitis and neuroendocrine tumours.


Patients who rely on the medication suffer severe abdominal cramps and a particularly unpleasant form of diarrhoea when they are unable to obtain it – typically taking a handful of the tablets with every meal to avoid these symptoms.

Lack of adequate PERT leads to malnutrition, with rapid weight loss, fatigue, vitamin and mineral deficiency, susceptibility to infections and, as many of these patients are diabetic, their blood sugars become increasingly difficult to control.

The shortage has been caused by a number of factors including supply chain issues across Europe exacerbated by leaving the European Union, the lack of a UK manufacturer and a worldwide increase in demand due to a rise in the number of patients living with the conditions related to it.

August 2024

In August we issues further coverage of our campaign to improve travel insurance cost and cover for cancer patients.



The screenshot shows the Change.org website interface for a petition. At the top left is the 'change.org' logo. Below it are two tabs: 'Petition details' (which is selected and underlined) and 'Comments'. A photograph of two women, one in a white t-shirt and one in a black jacket, stands by a body of water. Below the photo is the petition title: 'Ensure cancer patients are able to access affordable travel insurance'. Underneath the title, it says 'Started 5 July 2022' and 'Petition to Financial Conduct Authority'. A progress bar shows '133,612 Signatures' in purple text and '150,000 Next Goal' in black text.

September 2024

In September some of our patients from across the south, their clinicians and family members raised more than £9,500 by leaping from Europe's largest drop zone




October 2024

We reported that our UHS researchers funded by PLANETS found taking aspirin regularly cuts the risk of developing pancreatic cancer by 40% in people with diabetes – and by 20% in the general population.



February 2025

Research published in the journal Cancers and part-funded by PLANETS found patients with complex cancers of the abdomen and pelvis which were previously deemed inoperable are now surviving long-term thanks to developments in surgical techniques and expertise.



FINANCIAL REVIEW

Financial position

The Charity's financial position as of 31 March 2025 can be found in the Balance Sheet. As of 31 March 2025 the charity bank balance was £317,055 (plus £85,311, 85,000 and £89,163) in three high interest savings accounts). The charity generated income of £378,022 for the period from 1 April 2024 to 31 March 2025.

At the beginning of the financial year we had £205,130 ring fenced to go towards funding Research and Development Projects.

This year, PLANETS Cancer Charity funded several impactful initiatives:

- **Pancreatic Cancer Research**

We supported ongoing studies using UK Biobank data to improve early detection of pancreatic cancer, one of the deadliest cancer types.

- **Robotic Ultrasound Probe for HPB Surgery**

We funded a second robotic ultrasound probe for UHS to enhance precision in complex HPB surgeries, supporting the growth of the robotic surgery service.

- **Valley Cushions for Postoperative Recovery**

We provided specialist cushions to improve comfort and reduce wound complications in patients recovering from pelvic exenteration surgeries.

- **Theatre Caps for Surgical Teams**

We supplied new surgical caps to promote hygiene and comfort in operating theatres.

- **Medical Training Support**

We continued to invest in training and professional development for healthcare staff.

- **Patient Support** - We also funded numerous patient support days and conferences.

The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements.

FINANCIAL REVIEW - Reserves policy

For **2024/25** the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover 1 year of governance, management, fundraising and administration. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we ring fence those sums until enough money is available to meet the full cost of the project.

Help Us Raise £2 Million to Transform Cancer Care Over the Next Five Years

To meet our ambitious goals, we must raise **£2 million** over the next five years. This vital funding will enable us to provide:

- **£250,000** for direct patient support
- **£500,000** to advance research into PLANETS cancers
- **£750,000** for cutting-edge, innovative treatments

We are also committed to keeping our administrative costs below 25% of total turnover, ensuring your donations deliver the greatest possible impact.

In today's cost-conscious NHS environment, research and innovation are under threat. At PLANETS, we are determined to ensure that patients across our region—and beyond—continue to receive world-leading care and access to the latest treatments.

Your support will help us fund several critical initiatives, including:

- **The REMACS Study**

We are co-funding a PhD researcher in this important national study, focused on quality of life and outcome measures following various surgical techniques for advanced pelvic cancers such as recurrent rectal cancer.

- **Predictive Models for Pancreatic Cancer**

We're supporting research into genomic and clinical risk factors to predict those most at risk of developing pancreatic cancer. This includes funding laboratory costs for a dedicated PhD researcher using data from cancer patients and the UK Biobank.

- **Upper GI Cancer Network Data Controller (50% funded)**

Launched in January 2025, this 3-year project represents a significant step forward in strengthening the quality, consistency, and security of data collection within the Upper GI cancer network. The initiative is 50% funded by PLANETS Charity and reflects our ongoing commitment to advancing both clinical care and research across the region. The project will support the appointment of a dedicated **Data Controller**, who will play a pivotal role in managing cancer data across multiple trusts, ensuring it is collected, stored, and shared in a secure, standardised, and ethically compliant manner. By improving data accuracy and accessibility, this role will directly enhance patient care, clinical decision-making, and outcomes tracking. This is a **collaborative initiative** between **Dorset County Hospital, Portsmouth Hospitals University NHS Trust, and University Hospital Southampton**, designed to foster data integration and knowledge-sharing across institutions. Ultimately, the project aims to lay the foundation for a robust, region-wide Upper GI cancer dataset that can inform both local service improvements and national research priorities.

- **Development and testing of a new drug class in Pancreatic, Liver, and Neuroendocrine cancers.** Cancer remains one of the greatest medical challenges, with spread of the cancer (metastasis) and resistance to drug treatment (chemotherapy resistance) representing two of the main causes of cancer related death. We have previously showed that most cancers activate a key biological process called epithelial-mesenchymal transition (EMT) which leads to cancer spread and drug resistance, and that targeting this pathway can lead to cancer cell death. However, existing drugs that target this pathway have high toxicity. By collaborating with the Chemistry department at the University of Southampton, through a EPSRC research grant, we have now developed four novel compounds targeting this pathway that can kill Neuroendocrine, Hepatocellular and Pancreatic cancer but induce no harm in normal cells
- **Jet Vent Machine**
This advanced technology enables prolonged breath-hold techniques (60–90 minutes), significantly expanding the range and complexity of our liver ablation services, allowing us to treat more—and more complex—cases.
- **Da Vinci Robotic Surgery Console**
Funding a new Da Vinci surgical console will double the number of PLANETS cancer patients receiving minimally invasive robotic surgery at the regional cancer centre in Southampton. This will also help us establish UHS as a national training hub for robotic cancer surgery.

Why It Matters

Each of these projects represents a leap forward in **patient care, scientific understanding, and clinical innovation**. But none of it is possible without the generosity of people like you.

**Join us in shaping the future of cancer care.
Together, we can save lives.**



STRUCTURE, GOVERNANCE AND MANAGEMENT - Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

PLANETS is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution. The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number - 1175572

Principal address - Milestone Cottage, 113 Havant Rd, Emsworth, Hampshire, PO10 7LG

Chairman of trustees - Mr Neil Pearce

Trustees

Dr B Stedman

Professor A Mirnezami

Dr F Noble

Mr C Hoyland

Miss V Caine


Miss R M H Willrich

Independent Examiner

S Mackie, FCA, Morris Crocker, Chartered Accountants

Station House, North Street, Havant, Hampshire, PO9 1QU

Approved by order of the board of trustees on 31st October 2025
and signed on its behalf by:

A handwritten signature in black ink, appearing to read 'Dr B Stedman', is written over a light grey rectangular background.

Dr B Stedman - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PLANETS CANCER CHARITY**

Independent examiner's report to the trustees of Planets Cancer Charity

I report to the charity trustees on my examination of the accounts of Planets Cancer Charity (the Trust) for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Stuart Mackie

S Mackie, FCA

Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

Date: 11/11/25.....

PLANETS CANCER CHARITY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	141,221	128,224	269,445	363,955
Charitable activities					
Charitable activities	5	124	-	124	80
Other trading activities	3	103,958	-	103,958	55,852
Investment income	4	<u>4,495</u>	<u>-</u>	<u>4,495</u>	<u>9</u>
Total		<u>249,798</u>	<u>128,224</u>	<u>378,022</u>	<u>419,896</u>
EXPENDITURE ON					
Raising funds	6	37,693	-	37,693	28,739
Charitable activities					
Charitable activities	7	<u>179,866</u>	<u>25,194</u>	<u>205,060</u>	<u>208,025</u>
Total		<u>217,559</u>	<u>25,194</u>	<u>242,753</u>	<u>236,764</u>
NET INCOME		32,239	103,030	135,269	183,132
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>458,373</u>	<u>5,130</u>	<u>463,503</u>	<u>280,371</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>490,612</u></u>	<u><u>108,160</u></u>	<u><u>598,772</u></u>	<u><u>463,503</u></u>

The notes form part of these financial statements

PLANETS CANCER CHARITY

**BALANCE SHEET
31 MARCH 2025**

	Notes	2025 £	2024 £
CURRENT ASSETS			
Stocks	12	3,558	4,339
Debtors	13	21,024	-
Cash at bank		<u>576,550</u>	<u>460,617</u>
		601,132	464,956
CREDITORS			
Amounts falling due within one year	14	(2,360)	(1,453)
		<u>598,772</u>	<u>463,503</u>
NET CURRENT ASSETS			
		<u>598,772</u>	<u>463,503</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>598,772</u>	<u>463,503</u>
NET ASSETS			
		<u>598,772</u>	<u>463,503</u>
FUNDS	16		
Unrestricted funds		490,612	458,373
Restricted funds		<u>108,160</u>	<u>5,130</u>
TOTAL FUNDS		<u>598,772</u>	<u>463,503</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 10 November 2025 and were signed on its behalf by:

B Stedman - Trustee



The notes form part of these financial statements

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Financial instruments

The charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable investments in stocks and shares. The measurement basis used for these instruments is detailed below.

Debtors and cash at bank

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Cash at bank and in hand included cash held on deposit or in a current account.

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

1. ACCOUNTING POLICIES - continued

Financial instruments

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

2. DONATIONS AND LEGACIES

	2025	2024
	£	£
Donations	159,421	129,168
Legacies	-	33,949
Ring-fenced Donations - R&D	23,024	838
Ring fenced donations - Grange /R&D	-	200,000
Ring-fenced Donations - Robotics Project	25,000	-
Ring-fenced Donations - UGI Data Project	<u>62,000</u>	<u>-</u>
	<u>269,445</u>	<u>363,955</u>

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Fundraising events	<u>103,958</u>	<u>55,852</u>

4. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	<u>4,495</u>	<u>9</u>

All investment income is derived from assets held in the United Kingdom.

5. INCOME FROM CHARITABLE ACTIVITIES

		2025	2024
	Activity	£	£
Merchandising	Charitable activities	<u>124</u>	<u>80</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

6. RAISING FUNDS

Raising donations and legacies

	2025 £	2024 £
Fundraising expenditure	<u>37,693</u>	<u>28,739</u>

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 8) £	Totals £
Charitable activities	<u>192,045</u>	<u>13,015</u>	<u>205,060</u>

8. SUPPORT COSTS

	Management £	Finance £	Governance costs £	Totals £
Charitable activities	<u>8,120</u>	<u>276</u>	<u>4,619</u>	<u>13,015</u>

Support costs, included in the above, are as follows:

Management

	2025 Charitable activities £	2024 Total activities £
Computer costs	6,991	5,356
Training costs	-	945
Postage and stationery	<u>1,129</u>	<u>940</u>
	<u>8,120</u>	<u>7,241</u>

Finance

	2025 Charitable activities £	2024 Total activities £
Bank charges	<u>276</u>	<u>168</u>

Governance costs

	2025 Charitable activities £	2024 Total activities £
Professional fee	1,394	1,051
Trustee meeting expenses	1,104	957
Accountancy	1,509	1,386
Payroll	<u>612</u>	<u>487</u>
	<u>4,619</u>	<u>3,881</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

Trustees' expenses

During the year no trustees (2024: none) were reimbursed out of pocket expenses totalling £nil (2024: £nil).

10. STAFF COSTS

No employees received emoluments in excess of £60,000.

The key management personnel of the charity comprise the Operations Director, Chief Executive and Fundraising Officer with remuneration totalling £119,617 for 2025 (2024: £121,704).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	363,117	838	363,955
Charitable activities			
Charitable activities	80	-	80
Other trading activities	55,852	-	55,852
Investment income	<u>9</u>	<u>-</u>	<u>9</u>
Total	<u>419,058</u>	<u>838</u>	<u>419,896</u>
 EXPENDITURE ON			
Raising funds	28,739	-	28,739
Charitable activities			
Charitable activities	<u>195,215</u>	<u>12,810</u>	<u>208,025</u>
Total	<u>223,954</u>	<u>12,810</u>	<u>236,764</u>
 NET INCOME/(EXPENDITURE)	195,104	(11,972)	183,132
 RECONCILIATION OF FUNDS			
Total funds brought forward	<u>263,269</u>	<u>17,102</u>	<u>280,371</u>
 TOTAL FUNDS CARRIED FORWARD	<u>458,373</u>	<u>5,130</u>	<u>463,503</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025

12. STOCKS

	2025	2024
	£	£
Stocks	<u>3,558</u>	<u>4,339</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade debtors	<u>21,024</u>	<u>-</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Other creditors	<u>2,360</u>	<u>1,453</u>

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds	Restricted funds	2025 Total funds	2024 Total funds
	£	£	£	£
Current assets	492,972	108,160	601,132	464,956
Current liabilities	<u>(2,360)</u>	<u>-</u>	<u>(2,360)</u>	<u>(1,453)</u>
	<u>490,612</u>	<u>108,160</u>	<u>598,772</u>	<u>463,503</u>

16. MOVEMENT IN FUNDS

	At 1.4.24	Net movement in funds	At 31.3.25
	£	£	£
Unrestricted funds			
General fund	258,373	32,239	290,612
Grange donation	<u>200,000</u>	<u>-</u>	<u>200,000</u>
	458,373	32,239	490,612
Restricted funds			
R&D fund	5,130	(2,170)	2,960
Robotics Project	-	25,000	25,000
UGI Data Project	-	62,000	62,000
Patient Support	<u>-</u>	<u>18,200</u>	<u>18,200</u>
	<u>5,130</u>	<u>103,030</u>	<u>108,160</u>
TOTAL FUNDS	<u>463,503</u>	<u>135,269</u>	<u>598,772</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

16. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	249,798	(217,559)	32,239
Restricted funds			
R&D fund	23,024	(25,194)	(2,170)
Robotics Project	25,000	-	25,000
UGI Data Project	62,000	-	62,000
Patient Support	<u>18,200</u>	<u>-</u>	<u>18,200</u>
	<u>128,224</u>	<u>(25,194)</u>	<u>103,030</u>
TOTAL FUNDS	<u><u>378,022</u></u>	<u><u>(242,753)</u></u>	<u><u>135,269</u></u>

Comparatives for movement in funds

	At 1.4.23 £	Net movement in funds £	At 31.3.24 £
Unrestricted funds			
General fund	263,269	(4,896)	258,373
Grange donation	<u>-</u>	<u>200,000</u>	<u>200,000</u>
	263,269	195,104	458,373
Restricted funds			
R&D fund	<u>17,102</u>	<u>(11,972)</u>	<u>5,130</u>
TOTAL FUNDS	<u><u>280,371</u></u>	<u><u>183,132</u></u>	<u><u>463,503</u></u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	219,058	(223,954)	(4,896)
Grange donation	<u>200,000</u>	<u>-</u>	<u>200,000</u>
	419,058	(223,954)	195,104
Restricted funds			
R&D fund	<u>838</u>	<u>(12,810)</u>	<u>(11,972)</u>
TOTAL FUNDS	<u><u>419,896</u></u>	<u><u>(236,764)</u></u>	<u><u>183,132</u></u>

REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial.

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

16. MOVEMENT IN FUNDS - continued

Grange donation - Monies donated to be put towards suggested items by the donor but with ultimate discretion as to amounts, items and timing left to the trustees to maximise the donation.

Robotics Project - The project proposed is the acquisition of a new Da Vinci XI robot platform, to join the existing robotic fleet of 1 Da Vinci X (older model), 1 Da Vinci XI (the same as this one) and 1 CMR Robot. The current Da Vinci platforms are nearing 100% utilisation amongst colorectal, thoracic surgery, HPB surgery, Upper GI Surgery and Urology. This means that there are many patients in these specialities (approximately the same number as are currently being treated with robotic surgery) that could benefit from the enhanced clinical outcomes that robotic surgery can offer, particularly for those patients who can currently only be offered open surgery.

UGI Data Project - To enable dedicated and consistent, accurate, timely and secure data acquisition from clinical and basic/translational science sources building upon the existing successful infrastructure in the ITRG. We will extend data acquisition from UHS/UoS to include Portsmouth and Bournemouth patients.

Patient Support - Patient support groups for our patients covering each cancer type that PLANETS manage. This is covering patients in the Dorset and Hampshire areas (and beyond) and includes Cancer coaching , conferences and coffee mornings.

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2025.

PLANETS CANCER CHARITY

England & Wales - Charity number 1175572

Accounts

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2024



The trustees present their report with the financial statements of the charity for the year ended 31 March 2024 and have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

About PLANETS

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just over £2.2 million.

PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex.

Vision

Transforming cancer care in the south through our 'family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community.

Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other's contributions and work together with a shared vision. In line with our vision and objectives, we will ensure that:

- Patients and their families receive outstanding support
- The charity continues to support the provision of cutting-edge clinical care and treatment through investment in advanced and innovative treatments
- We consider our donors and beneficiaries in everything we do
- We are accountable for how we spend our income and the impact it makes
- We strive for continuous development and improvement of our team and the support and experience we provide
- We help drive a change in attitudes amongst health care professionals and the public to generate optimism around PLANETS cancers and their treatment

Our goals

- 1) Improve patient outcomes: Longer survival and a better quality of life through early diagnosis and enhanced treatment conditions.
- 2) Better patient experience: Improved support, information communication and facilities for patients.
- 3) Assist the development of our centres: We can only achieve goals 1 and 2 by facilitating the development of our clinical teams and centres, so we can attract funding for clinical support, diagnosis, therapeutics and research.

Objectives and activities

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments, and research.

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities. The trustees refer to public benefit throughout this report.

ACHIEVEMENT AND PERFORMANCE - Charitable activities

Since inception in 2011, starting as a hospital charity fund and subsequently forming an independent charity in 2019, PLANETS Cancer Charity has built a strong community of patients, carers and healthcare professionals.

Over the past 13 years we have achieved more than anyone thought possible. We have:

Established a network of patient support groups and conferences, for pancreatic, colorectal and neuroendocrine cancer types across the Wessex region.

Fundraised £1 million for the introduction of intra operative radiotherapy (IORT) with the UK's first mobile electron beam radiotherapy machine which can deliver radiotherapy to advanced cancers during surgery. This machine has already treated over 200 patients (Dec 2022) and is expected to treat another 2,000 during its lifetime. It has helped deliver ground-breaking results – published in leading international medical journals – by drastically reducing recurrence rates for these aggressive cancers.

Funded full-time pancreatic and neuroendocrine tumour PhD and MD researchers to work with the clinician scientists in Southampton's world leading cancer immunology research department.

Year in review – April 2023 to 31 March 2024

This has been another important year for the charity as we continue to establish ourselves on a long-term, sustainable footing as an independent charity. Previously we managed with volunteer support, rather than staff on the payroll. We have now moved from this arrangement to paid employment for our CEO and Director of operations as well as a new Fundraising and Events Officer role from April 2023. This additional resource has been an essential part of our charities journey and will allow us to provide a better, more comprehensive and professional service in the future. Establishing ourselves on this more formal, professional basis will enable the further growth of the charity as we seek to achieve our charitable goals.

This continued development of our charity has also seen a greater involvement of our Board of Trustees, with establishment of subcommittee groups to ensure close review of finance, events, patient support and projects on a regular basis. This is an essential part of our governance structure.

This year has also seen us increase our media profile, by publicising stories related to our fundraising projects, patient support initiatives, research, treatment programs and advocating for issues that seriously affect our patients.

Some of the stories which we have published in the media this year include:

May 2023

PLANETS announced its petition calling for patients to be offered affordable travel insurance had secured more than 132,000 signatures.

The screenshot shows a petition on change.org. At the top, the change.org logo is visible. Below it, there are tabs for 'Petition details' and 'Comments'. A photograph shows two women standing by a body of water. The main title of the petition is 'Ensure cancer patients are able to access affordable travel insurance'. Below the title, it says 'Started 5 July 2022' and 'Petition to Financial Conduct Authority'. A progress bar shows that 133,612 signatures have been collected, with a next goal of 150,000 signatures.

It was started after we warned that cancer patients were being denied valuable holiday respite due to extortionate costs. In some cases, insurers will not cover patients at all.

Following the success of the petition, we wrote to the Financial Conduct Authority (FCA), the UK's financial regulator which oversees the travel insurance industry, to highlight the issues. This has resulted in PLANETS being asked to collaborate with the FCA, as well as the Association of British Insurers (ABI), to support a review and put forward proposals to overcome some of the challenges being faced.

July 2023

PLANETS highlighted how we had developed a unique exercise referral pathway for patients to boost recovery from treatment. It offers patients access to a qualified fitness expert as a routine part of their care following diagnosis.



September 2023

We ran a press release on one of our cancer patients who has undergone traumatic but life-saving surgery who is spearheading a research project that aims to transform treatment options and outcomes for others in the future.

PLANETS have helped to fund the project, Reconstruction in Extended Margin Cancer Surgery (REMACS) – which is underway to investigate complication frequency, quality of life and financial implications following different reconstruction techniques. It is hoped the study will improve patient and doctor decision-making and find the best methods of reconstruction to improve outcomes.

The study is being led by researchers at University Hospital but taking place at eight sites across England.

October 2023

In October we raised an incredible £34,934 at our car rally event – Scrap the future Part 3!

Starting at Popham Airfield, with fun Top Gear style challenges then onto Doncaster, the halfway mark, before ending the long journey to Cameron House on Loch Lomond. It was amazing to see so much effort was put into these car transformations and to have so many teams involved.


Our Scrap car rallies are always a highlight, as well as being a great way to raise money and awareness.



November 2023

We marked World Pancreatic Cancer Day by unveiling an “inspiring and emotional” short, promotional film about PLANETS; the challenges of a cancer diagnosis and how we are working with patients and the clinical teams transforming care.

The film highlights the charity’s commitment to making a difference to the lives of cancer patients and features a number of those helped by PLANETS in recent years. It also shows members of the PLANETS clinical and fundraising teams, explaining how fundraising for the charity changes lives.




We announced that surgeons in Southampton would be the first in the UK to begin using 3D printed models of patients' livers to help them perform complex cancer operations. The story received widespread local and national media coverage.

Converting the data available from CT and MRI scans of patients with hilar cholangiocarcinoma – a type of bile duct cancer – into 3D models will enable better planning and decision-making prior to surgery.

As the cancer occurs in the bile ducts that lead out of the liver and join with the gallbladder, it is frequently difficult for surgeons to establish whether a tumour can be safely removed or not until the operation is underway.

As a result, this can lead to “irreversible steps” being taken that may result in poor short and long-term outcomes for patients. By using 3D printed models tailored to each patient, clinicians will be able to assess the tumour and its close attachments such as blood vessels and bile ducts at scale pre-surgery.

The project is led by Mr Arjun Takhar, a consultant hepatobiliary and pancreatic cancer surgeon at University Hospital Southampton, who is part of a team of experts supported by PLANETS, which is funding the pilot study and has received a £2,000 grant from The Hospital Saturday Fund to put towards the initiative.



A new wellbeing room funded by PLANETS opened for patients with liver diseases at University Hospital Southampton.

The facility, located on the gastroenterology and hepatology ward, provides a quiet space for patients and a place for private conversations which would previously have taken place at the bedside.

It offers the opportunity for patients to relax on the sofa and watch TV and there are plans to add weights and cardio equipment in the coming months.

PLANETS contributed £12,000 for the development which was made possible through a partnership with property developer Taylor Wimpey Southern Counties, which raised more than £20,000 for the charity over 2023 after making it the company's 'charity of the year'.



FINANCIAL REVIEW

Financial position

The Charity's financial position as of 31 March 2024 can be found in the Balance Sheet. As of 31 March 2024 the charity bank balance was £375,616.55 (and £85,000 currently in a high interest savings account). The charity generated income of £419,896 for the period from 1 April 2023 to 31 March 2024.

At the beginning of the financial year we had £17,102 ringfenced to go towards funding Research and Development Projects.

Throughout the year we funded the following R&D:

- The Reconstruction in Extended Margin Cancer Surgery (REMACS) study which is investigating the quality of life and health economic outcomes from perineal reconstruction in abdominopelvic cancer patients.
- Ongoing research into pancreatic cancer-associated diabetes, genetic variants and metabolomic analysis using the UK biobank cohort to help develop effective strategies for the early detection of pancreatic cancer which is considered to have the worst survival outcome among cancers.

We also funded the following projects:

- Trial of 3D printed models of livers based on patients' CT scans to allow for better personalised planning of their operations by creating exact replicas of the organ.
- A new wellbeing room at University Hospital Southampton within the gastroenterology and hepatology. This provides a quiet space for private conversations as well as the opportunity for patients to relax or exercise using weights or cardio equipment to maintain their physical condition.
- A NET dietitian was jointly funded with the Robert White Trust to help patients across the Wessex NET group area, including attendance at the weekly NET MDT as well as at the monthly NET clinics in Dorchester, Poole, Bournemouth, Southampton, and Portsmouth. The role is also designed to include education of patients and other members of the clinical service around the region about dietary management of NET patients. (Funding started in May 2021 at a cost of £5k per month) our liability for this ended July 2023 with the hospital trusts now supporting this role permanently.
- We also funded numerous patient support days and conferences.

The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements.

FINANCIAL REVIEW

Reserves policy

For 2023/24 the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover 1 year of governance, management, fundraising and administration. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we ringfence those sums until enough money is available to meet the full cost of the project.

FUTURE PLANS

We need to raise £2 million over the next five years to achieve our goals of providing at least £250,000 for patient support, £500,000 for research into PLANETS cancers and £750,000 for innovative treatments, whilst also covering our administrative costs which we aim to keep below 25% of turnover.

In the current, cost-cutting NHS environment, research and innovation is in danger of being sidelined. The PLANETS team aim to ensure that patients across our region and further afield still have access to the best available care. We are committed to funding several further projects including:

The ongoing support of the REMACS study. This is a national study and we are co-funding a PhD researcher looking at quality of life and outcome measures after a range of different surgical techniques for managing advanced pelvic cancers, such as recurrent rectal cancer.

Ongoing research into predictive models for identifying people at risk of developing pancreatic cancer, using genomic data from cancer patients and the UK biobank as well as clinical risk factors. We are committed to funding laboratory costs for a PhD researcher.

50% Part funding an Upper GI Cancer Network Data Controller post to enable dedicated and consistent, accurate, timely and secure data acquisition from clinical and basic/translational science sources. Over the 3-year lifecycle of the project, we aim to explore options for automation of data extraction and acquisition via development of our existing relationships with the Clinical Informatics Research Unit and the Social Data Foundation.

We are looking to support a clinical trial of chemosaturation therapy for secondary liver cancer which works by isolating the liver from the rest of the body and 'bathing' it in much larger doses of chemotherapy than would normally be possible because it does not enter the bloodstream.

We are also looking at potential collaboration with Southampton Hospitals Charity to each fund 25% of the cost of a new Da Vinci surgical robot, to double the number of PLANETS Cancer patients offered minimally invasive robotic surgery at the regional cancer centre in Southampton and establish UHS as a national training centre for robotic cancer surgery.



STRUCTURE, GOVERNANCE AND MANAGEMENT - Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

PLANETS is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution. The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number - 1175572

Principal address - Milestone Cottage, 113 Havant Rd, Emsworth, Hampshire, PO10 7LG

Chairman of trustees - Mr Neil Pearce

Trustees

- Dr B Stedman
- Professor A Mirnezami
- Dr F Noble
- Mr C Hoyland
- Miss V Caine
- Miss R M H Willrich

Independent Examiner
S Mackie, FCA, Morris Crocker, Chartered Accountants

Station House, North Street, Havant, Hampshire, PO9 1QU

Approved by order of the board of trustees on 10th Oct 2024 and signed on its behalf
by:

..... Dr B Stedman -Trustee



**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PLANETS CANCER CHARITY**

Independent examiner's report to the trustees of Planets Cancer Charity

I report to the charity trustees on my examination of the accounts of Planets Cancer Charity (the Trust) for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.


Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



S Mackie, FCA

Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

Date: 22 October 2024

PLANETS CANCER CHARITY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2024**

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	363,117	838	363,955	100,382
Charitable activities					
Charitable activities	5	80	-	80	1,325
Other trading activities	3	55,852	-	55,852	71,896
Investment income	4	<u>9</u>	<u>-</u>	<u>9</u>	<u>-</u>
Total		<u>419,058</u>	<u>838</u>	<u>419,896</u>	<u>173,603</u>
EXPENDITURE ON					
Raising funds	6	28,739	-	28,739	30,524
Charitable activities					
Charitable activities	7	<u>195,215</u>	<u>12,810</u>	<u>208,025</u>	<u>178,097</u>
Total		<u>223,954</u>	<u>12,810</u>	<u>236,764</u>	<u>208,621</u>
NET INCOME/(EXPENDITURE)		195,104	(11,972)	183,132	(35,018)
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>263,269</u>	<u>17,102</u>	<u>280,371</u>	<u>315,389</u>
TOTAL FUNDS CARRIED FORWARD		<u>458,373</u>	<u>5,130</u>	<u>463,503</u>	<u>280,371</u>

PLANETS CANCER CHARITY

**BALANCE SHEET
31 MARCH 2024**

	Notes	2024 £	2023 £
CURRENT ASSETS			
Stocks	12	4,339	4,451
Debtors	13	-	650
Cash at bank		<u>460,617</u>	<u>276,620</u>
		464,956	281,721
CREDITORS			
Amounts falling due within one year	14	<u>(1,453)</u>	<u>(1,350)</u>
NET CURRENT ASSETS		<u>463,503</u>	<u>280,371</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>463,503</u>	<u>280,371</u>
NET ASSETS			
		<u>463,503</u>	<u>280,371</u>
FUNDS			
	16		
Unrestricted funds		458,373	263,269
Restricted funds		<u>5,130</u>	<u>17,102</u>
TOTAL FUNDS		<u>463,503</u>	<u>280,371</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 16th of June 2024 and were signed on its behalf by:



.....
B Stedman - Trustee

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

2. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	129,168	99,583
Legacies	33,949	799
Ring-fenced Donations - R&D	838	-
Ring fenced donations - Grange	<u>200,000</u>	<u>-</u>
	<u>363,955</u>	<u>100,382</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

3. OTHER TRADING ACTIVITIES

	2024 £	2023 £
Fundraising events	<u>55,852</u>	<u>71,896</u>

4. INVESTMENT INCOME

	2024 £	2023 £
Deposit account interest	<u>9</u>	<u>-</u>

All investment income is derived from assets held in the United Kingdom.

5. INCOME FROM CHARITABLE ACTIVITIES

	Activity Charitable activities	2024 £	2023 £
Merchandising		<u>80</u>	<u>1,325</u>

6. RAISING FUNDS

Raising donations and legacies

	2024 £	2023 £
Fundraising expenditure	<u>28,739</u>	<u>30,524</u>

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 8) £	Totals £
Charitable activities	<u>196,735</u>	<u>11,290</u>	<u>208,025</u>

8. SUPPORT COSTS

	Management £	Finance £	Governance costs £	Totals £
Charitable activities	<u>7,241</u>	<u>168</u>	<u>3,881</u>	<u>11,290</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

8. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

Management

	2024 Charitable activities	2023 Total activities
	£	£
Computer costs	5,356	3,356
Training costs	945	263
Postage and stationery	<u>940</u>	<u>1,437</u>
	<u>7,241</u>	<u>5,056</u>

Finance

	2024 Charitable activities	2023 Total activities
	£	£
Bank charges	<u>168</u>	<u>164</u>

Governance costs

	2024 Charitable activities	2023 Total activities
	£	£
Professional fee	1,051	734
Trustee meeting expenses	957	248
Donor meeting expenses	-	806
Accountancy	1,386	1,350
Payroll	<u>487</u>	<u>270</u>
	<u>3,881</u>	<u>3,408</u>

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2024 nor for the year ended 31 March 2023.

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024**

9. TRUSTEES' REMUNERATION AND BENEFITS - continued

Trustees' expenses

During the year no trustees (2023: none) were reimbursed out of pocket expenses totalling £nil (2023: £nil).

10. STAFF COSTS

No employees received emoluments in excess of £60,000

The key management personnel of the charity comprise the Operations Director, Chief Executive and Fundraising Officer with remuneration totalling £121,704 for 2023 (2023: £73,182).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	100,382	-	100,382
Charitable activities			
Charitable activities	1,325	-	1,325
Other trading activities	<u>71,896</u>	<u>-</u>	<u>71,896</u>
Total	<u>173,603</u>	<u>-</u>	<u>173,603</u>
EXPENDITURE ON			
Raising funds	30,524	-	30,524
Charitable activities			
Charitable activities	<u>178,097</u>	<u>-</u>	<u>178,097</u>
Total	<u>208,621</u>	<u>-</u>	<u>208,621</u>
NET INCOME/(EXPENDITURE)	(35,018)	-	(35,018)
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>298,287</u>	<u>17,102</u>	<u>315,389</u>
TOTAL FUNDS CARRIED FORWARD	<u>263,269</u>	<u>17,102</u>	<u>280,371</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

12. STOCKS			2024	2023
			£	£
Stocks			<u>4,339</u>	<u>4,451</u>
13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR			2024	2023
			£	£
Trade debtors			<u>-</u>	<u>650</u>
14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR			2024	2023
			£	£
Other creditors			<u>1,453</u>	<u>1,350</u>
15. ANALYSIS OF NET ASSETS BETWEEN FUNDS			2024	2023
	Unrestricted funds	Restricted funds	Total funds	Total funds
	£	£	£	£
Current assets	459,826	5,130	464,956	281,721
Current liabilities	<u>(1,453)</u>	<u>-</u>	<u>(1,453)</u>	<u>(1,350)</u>
	<u>458,373</u>	<u>5,130</u>	<u>463,503</u>	<u>280,371</u>
16. MOVEMENT IN FUNDS			Net movement in funds	At
		At 1.4.23	in funds	31.3.24
		£	£	£
Unrestricted funds				
General fund		263,269	(4,896)	258,373
Grange donation		<u>-</u>	<u>200,000</u>	<u>200,000</u>
		263,269	195,104	458,373
Restricted funds				
R&D fund		17,102	(11,972)	5,130
		<u>-</u>	<u>-</u>	<u>-</u>
TOTAL FUNDS		<u>280,371</u>	<u>183,132</u>	<u>463,503</u>

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

16. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	219,058	(223,954)	(4,896)
Grange donation	<u>200,000</u>	<u>-</u>	<u>200,000</u>
	419,058	(223,954)	195,104
Restricted funds			
R&D fund	838	(12,810)	(11,972)
	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>419,896</u>	<u>(236,764)</u>	<u>183,132</u>

Comparatives for movement in funds

	At 1.4.22 £	Net movement in funds £	Transfers between funds £	At 31.3.23 £
Unrestricted funds				
General fund	298,287	(35,018)	(60,000)	203,269
REMACS R&D fund	<u>-</u>	<u>-</u>	<u>60,000</u>	<u>60,000</u>
	298,287	(35,018)	-	263,269
Restricted funds				
R&D fund	17,102	-	-	17,102
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>315,389</u>	<u>(35,018)</u>	<u>-</u>	<u>280,371</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	173,603	(208,621)	(35,018)
	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>173,603</u>	<u>(208,621)</u>	<u>(35,018)</u>

REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial.

Grange donation - Monies donated to be put towards suggested items by the donor but with ultimate discretion as to amounts, items and timing left to the trustees to maximise the donation.

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024**

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2024.

PLANETS CANCER CHARITY

England & Wales - Charity number 1175572

Accounts



REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
FOR PLANETS CANCER CHARITY

REGISTERED CHARITY NUMBER: 1175572

REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 31 MARCH 2023

The trustees present their report with the financial statements of the charity for the year ended 31 March 2023.

The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

About PLANETS

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just under £2 million.

PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex.

Vision

Transforming cancer care in the south through our 'family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community.

Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other's contributions and work together with a shared vision.

In line with our vision and objectives, we will ensure that:

- Patients and their families receive outstanding support

– published in leading international medical journals – by drastically reducing recurrence rates for these aggressive cancers.

- Funded full-time pancreatic and neuroendocrine tumour PhD and MD researchers to work with the clinician scientists in Southampton’s world leading cancer immunology research department.
- Helped to achieve European Neuroendocrine Cancer Centre of Excellence status (2016).
- Funded Hyperthermic intraperitoneal chemotherapy (HiPeC) at University Hospital Southampton NHS Foundation Trust (UHS), one of the first centres in the UK to use this treatment.
- Funded a full-time neuroendocrine tumour dietitian, one of the first in the UK, specialising in helping patients from across the region, with these rare cancers with serious effects on the digestive system.
- Invested in a range of small projects supporting treatment and care for PLANETS cancer patients from ultrasound machines, 3D anatomical models for outpatients, radioisotope delivery equipment, DAB radios for radiotherapy bunkers, psychotherapy sessions for patients struggling with their cancer diagnosis and targeted fitness support for cancer patients among many other small but significant and important items to assist cancer patients on their journey.

All of this has brought our local cancer community together.

In line with our charitable goals, all funds we raise are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

Year in review – April 2022 to 31 March 2023

This has been a really important transitional year for the charity as we continue to establish ourselves on a long-term, sustainable footing as an independent charity. Previously we managed with volunteer support, rather than staff on the payroll. We have now moved from this arrangement, through a period of ad hoc payments for staff, through to paid employment for our CEO and director of operations. This has been an essential part of our charities journey and will allow us to provide a better, more comprehensive and professional service in the future. Whilst we have been extremely successful for a volunteer led charity, the impact on work life balance for our volunteer staff has been enormous as they try to balance their charity commitments, with family life and other paid employment. This move to paid staff, has coincided with the resumption of many normal fundraising activities, which were heavily curtailed during the Covid 19 pandemic. Establishing ourselves on this more formal, professional basis will enable the further growth of the charity as we seek to achieve our charitable goals.

The development of our charity has also seen a greater involvement of our Board of Trustees, in particular with oversight of financial expenditure with establishment of a finance committee to ensure close review of accounts on a monthly basis. This is an essential part of our governance structure.





Later in May we reported the start of the ELECTRA trial. This is the first national clinical trial using PLANETS funded intraoperative electron beam radiotherapy (IORT) via the Mobetron machine at University Hospital Southampton. People undergoing surgery for rectal cancer that has spread into the pelvis have since been invited to join the trial, which aims to see whether the treatment can improve surgical outcomes. The trial, led by PLANETS team member Alex Mirnezami, professor of surgical oncology and consultant colorectal surgeon at UHS, is funded by Mobetron manufacturer IntraOp and endorsed by Cancer Research UK with funding support from PLANETS.



In July, PLANETS warned many patients are unable to secure affordable travel insurance – or even any at all – and in conjunction with the national Cancer52 charity embarked on a media campaign and petition to tackle the issue. The petition – launched on Change.org – has since secured more than 130,000 signatures. Subsequently PLANETS wrote to the Financial Conduct Authority (FCA), the UK’s financial regulator which oversees the travel insurance industry, to highlight the issues. This has resulted in PLANETS being asked to collaborate with the FCA, as well as the Association of British Insurers (ABI), to support a review and put forward proposals to overcome some of the challenges being faced. This work has received significant national media attention and is ongoing into the current year.

PLANETS thanked its supporters after completing an 8 year, £1 million fundraising campaign and making the final payment in January 2022 for the pioneering intraoperative electron beam radiotherapy machine Mobetron at University Hospital Southampton. It remains the only centre in the country to offer the treatment. This uses high energy electron beams delivered with precision to a very specific location inside the body immediately after a cancer has been removed. Around 190 patients from across the UK, have been treated with the technology in Southampton since its introduction with impressive results, reported in the British Journal of Surgery and World Journal of Surgical Oncology.

FINANCIAL REVIEW

Reserves policy

For 2022/23 the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover 1 year of expenditure £208,621. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we retain those sums in a designated fund until enough money is available to meet the full cost of the project.

FUTURE PLANS

We need to raise £1.5 million over the next five years to achieve our goals of providing £250,000 for patient support, £500,000 for research into PLANETS cancers and £750,000 for innovative treatments.

In the current, cost-cutting NHS environment, research and innovation is in danger of being sidelined. The PLANETS team aim to ensure that patients across our region and further afield still have access to the best available care.

A NET dietitian has been jointly funded with the Robert White Trust to help patients across the Wessex NET group area, including attendance at the weekly NET MDT as well as at the monthly NET clinics in Dorchester, Poole, Bournemouth, Southampton, and Portsmouth. The role is also designed to include education of patients and other members of the clinical service around the region about dietary management of NET patients. (Funding started in May 2021 at a cost of £5k per month) our liability for this ends July 2023.

We have introduced a formal process for inviting application for funding projects for investment in patient support projects, research or therapeutics.

We are committed to funding several further projects including:

- The REMACS study. This is a national study and we are co-funding a PhD researcher looking at quality of life and outcome measures after a range of different surgical techniques for managing advanced pelvic cancers, such as recurrent rectal cancer.
- Ongoing research into predictive models for identifying people at risk of developing pancreatic cancer, using genomic data from cancer patients and the UK biobank as well as clinical risk factors. We are committed to funding laboratory costs for a PhD researcher.
- Conversion of a room within the gastroenterology and hepatology ward footprint at UHS into a wellbeing room for PLANETS patients. This will provide a quiet space for private conversations as well as the opportunity for patients to relax or exercise using weights or cardio equipment to maintain their physical condition.
- A peptide receptor radionuclide therapy (PRRT) manual dose injector at Dorset hospital. This is a new cancer treatment service and the equipment is designed to reduce radiation exposure when treating patients with targeted radioisotope therapy.

Following our initial request for applications for funding we have several exciting new possibilities, which require additional information before we can decide whether to commit to supporting them,

Trustees

Dr B Stedman

Professor A Mirnezami

Professor T Underwood

Mr C Hoyland

Miss V Caine

Miss R M H Willrich

Miss E L Medway


Mr R J Griffiths (resigned 31.1.2022)

Independent Examiner

S Mackie, FCA, Morris Crocker, Chartered Accountants

Station House, North Street, Havant, Hampshire, PO9 1QU

Approved by order of the board of trustees on 15th November 2023 and signed on its behalf by:



Dr B Stedman - Trustee

PLANETS CANCER CHARITY

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 MARCH 2023

PLANETS CANCER CHARITY
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	100,382	-	100,382	452,582
Charitable activities	4				
Charitable activities		1,325	-	1,325	1,118
Other trading activities	3	71,896	-	71,896	14,532
Total		<u>173,603</u>	<u>-</u>	<u>173,603</u>	<u>468,232</u>
EXPENDITURE ON					
Raising funds	5	30,524	-	30,524	25,112
Charitable activities	6				
Charitable activities		178,097	-	178,097	294,123
Total		<u>208,621</u>	<u>-</u>	<u>208,621</u>	<u>319,235</u>
NET INCOME/(EXPENDITURE)		(35,018)	-	(35,018)	148,997
RECONCILIATION OF FUNDS					
Total funds brought forward		298,287	17,102	315,389	168,568
TOTAL FUNDS CARRIED FORWARD		<u>263,269</u>	<u>17,102</u>	<u>280,371</u>	<u>317,565</u>

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2023

3. OTHER TRADING ACTIVITIES				
			2023	2022
			£	£
Fundraising events			<u>71,896</u>	<u>14,532</u>
4. INCOME FROM CHARITABLE ACTIVITIES				
			2023	2022
	Activity		£	£
	Charitable activities			
Merchandising			<u>1,325</u>	<u>1,118</u>
5. RAISING FUNDS				
Raising donations and legacies				
			2023	2022
			£	£
Fundraising expenditure			<u>30,524</u>	<u>25,112</u>
6. CHARITABLE ACTIVITIES COSTS				
		Direct	Support	Totals
		Costs	costs (see	
		£	note 7)	£
Charitable activities			£	
		<u>169,469</u>	<u>8,628</u>	<u>178,097</u>
7. SUPPORT COSTS				
		Management	Finance	Governance
		£	£	costs
				£
Charitable activities				Totals
		<u>5,056</u>	<u>164</u>	<u>3,408</u>
				<u>8,628</u>

Support costs, included in the above, are as follows:

Management

		2023	2022
		Charitable	Total
		activities	activities
		£	£
Computer costs		3,356	1,972
Training costs		263	1,384
Postage and stationery		1,437	269
Sundries		-	131
		<u>5,056</u>	<u>3,756</u>

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2023

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued				
	Unrestricted funds	Restricted funds	Total funds	
	£	£	£	
Raising funds	25,112	-	25,112	
Charitable activities				
Charitable activities	83,020	211,103	294,123	
Total	108,132	211,103	319,235	
NET INCOME/(EXPENDITURE)	337,448	(188,451)	148,997	
Transfers between funds	(145,098)	145,098	-	
Net movement in funds	192,350	(43,353)	148,997	
RECONCILIATION OF FUNDS				
Total funds brought forward	108,113	60,455	168,568	
TOTAL FUNDS CARRIED FORWARD	300,463	17,102	317,565	
11. STOCKS				
		2023	2022	
		£	£	
Stocks		4,451	2,514	
12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR				
		2023	2022	
		£	£	
Trade debtors		650	-	
13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR				
		2023	2022	
		£	£	
Other creditors		1,350	1,585	
14. ANALYSIS OF NET ASSETS BETWEEN FUNDS				
	Unrestricted funds	Restricted funds	2023 Total funds	2022 Total funds
	£	£	£	£
Current assets	264,619	17,102	281,721	319,150
Current liabilities	(1,350)	-	(1,350)	(1,585)
	<u>263,269</u>	<u>17,102</u>	<u>280,371</u>	<u>317,565</u>

NOTES TO THE FINANCIAL STATEMENTS - continued**FOR THE YEAR ENDED 31 MARCH 2023****15. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	445,580	(108,132)	337,448
Restricted funds			
IORT fund	11,550	(211,103)	(199,553)
R&D fund	11,102	-	11,102
	<u>22,652</u>	<u>(211,103)</u>	<u>(188,451)</u>
TOTAL FUNDS	<u>468,232</u>	<u>(319,235)</u>	<u>148,997</u>

IORT fund - Planets hold a contract to pay the hospital monthly instalments for the lease purchase of the IORT machine. Planets does not own it as it is gifted to the hospital. This lease was fully paid off during the financial year.

REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2023.

PLANETS CANCER CHARITY

England & Wales - Charity number 1175572

Accounts

REGISTERED CHARITY NUMBER: 1175572

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022
FOR
PLANETS CANCER CHARITY**

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 12

PLANETS CANCER CHARITY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2022

The trustees present their report with the financial statements of the charity for the year ended 31 March 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Planets helps patients with pancreatic, liver, colorectal, abdominal, and neuroendocrine cancer. Funding patient support groups, innovative treatments, and research. Establishing a network of patient support groups across the Wessex region. Funding the introduction of intra operative radiotherapy (IORT) with the UK's first mobile electron beam radiotherapy machine, able to deliver radiotherapy to advanced cancers during surgery. Funding a HIPEC machine and a full-time pancreatic and neuroendocrine tumour researcher to work with the clinician scientists in Southampton's world leading cancer immunology research department.

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities. The trustees refer to public benefit throughout this report.

ACHIEVEMENT AND PERFORMANCE

Charitable activities

We have seen our intra-operative electron beam radiotherapy (IORT) program in Southampton delivering world-class, combined surgical and radiotherapy treatments to patients with advanced cancers from across our central South coast region. The UK's only electron beam radiotherapy machine and have now fully paid for the machine.

We have funded a full time pancreatic and Neuroendocrine tumour researcher to work with the clinician scientists in Southampton's world leading cancer immunology research department.

Funded the HIPEC machine - a form of Intra- abdominal heated chemotherapy treatment which is now being used as a treatment option for advanced cancers

Funded a specialist dietitian role for cancer patients

Funded the training for a prehab/rehab role for patients undergoing surgery

Supported a network of patient support groups and patient Conferences and patient psychotherapy sessions.

All of which have brought our local cancer community together.

In line with our Charitable goals all our funds raised are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

FINANCIAL REVIEW

Financial position

The Charity's financial position as at 31 March 2022 can be found in the Balance Sheet. As at 31 March 2022 the charity bank balance was £316,636. The charity generated income of £468,232 for the period from 1 April 2021 to 31 March 2022.

We carried out a campaign during covid and donations of £66,005 were ringfenced for the IORT fund. We also received a legacy payment of £338,776 in October 2021 which we used in part to pay the IORT machine off. This machine was paid in a full and final discounted settlement of £211,103 on 31st January 2022.

The Trustees have assessed the specific uncertainties surrounding the Covid 19 pandemic and have adapted the strategy of the charity to this new environment. Even though the full impact remains difficult to quantify the Trustees acknowledge that there has been an impact on fundraising events for 2021/22. The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements.

PLANETS CANCER CHARITY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2022

FINANCIAL REVIEW

Reserves policy

For 2021/22 the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover two year's governance, management, fundraising and administration, which in 2022/23 are budgeted to be £216,264. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment (although the Charity holds no such obligation at present), we retain those sums in a designated fund until enough money is available to meet the full cost of the project.

FUTURE PLANS

Our ongoing commitment to patient support requires £75,000 over the next five years.

We will aim to raise £60,000 over the next 3 years to fundraise for the set up and implementation of our Cancer Rehab Scheme.

We aim to raise another £250,000 over the next five years towards research into the immunology and tumour micro-environment of pancreatic and neuroendocrine cancers.

A NET dietitian has been jointly funded with the Robert White Trust to help patients across the Wessex NET group area, including attendance at the weekly NET MDT as well as at the monthly NET clinics in Dorchester, Poole, Bournemouth, Southampton, and Portsmouth. The role is also designed to include education of patients and other members of the clinical service around the region about dietary management of NET patients. (Funding started in May 2021 at a cost of £5k per month).

We also want to raise £500k over 5 years towards innovative treatments.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Planets is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution.

The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1175572

Principal address

Milestone Cottage
113 Havant Rd
Emsworth
Hampshire
PO10 7LG

Trustees

Professor T Underwood

N W Pearce

Dr B Stedman

Miss V Caine

Miss R M H Willrich

Miss E L Dolan

R J Griffiths (resigned 31.1.2022)

Professor A Mirnezami

C Hoyland (appointed 1.2.2022)

PLANETS CANCER CHARITY
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2022

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

S Mackie, FCA

ICAEW

Morris Crocker

Chartered Accountants

Station House


North Street

Havant

Hampshire

PO9 1QU

Approved by order of the board of trustees on 19 July 2022 and signed on its behalf by:


.....
Dr B Stedman - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PLANETS CANCER CHARITY**

Independent examiner's report to the trustees of Planets Cancer Charity

I report to the charity trustees on my examination of the accounts of Planets Cancer Charity (the Trust) for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.


Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



S Mackie, FCA
ICAEW
Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

Date: 26 July 2022

PLANETS CANCER CHARITY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	Unrestricted fund £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	429,930	22,652	452,582	134,558
Charitable activities					
Charitable activities	4	1,118	-	1,118	730
Other trading activities	3	14,532	-	14,532	-
Total		445,580	22,652	468,232	135,288
EXPENDITURE ON					
Raising funds	5	25,112	-	25,112	-
Charitable activities					
Charitable activities	6	83,020	211,103	294,123	185,099
Total		108,132	211,103	319,235	185,099
NET INCOME/(EXPENDITURE)		337,448	(188,451)	148,997	(49,811)
Transfers between funds	13	(145,098)	145,098	-	-
Net movement in funds		192,350	(43,353)	148,997	(49,811)
RECONCILIATION OF FUNDS					
Total funds brought forward		108,113	60,455	168,568	218,379
TOTAL FUNDS CARRIED FORWARD		300,463	17,102	317,565	168,568


The notes form part of these financial statements

PLANETS CANCER CHARITY

**BALANCE SHEET
31 MARCH 2022**

	Notes	2022 £	2021 £
CURRENT ASSETS			
Stocks	10	2,514	1,750
Cash at bank		316,636	167,298
		<u>319,150</u>	<u>169,048</u>
CREDITORS			
Amounts falling due within one year	11	(1,585)	(480)
		<u>317,565</u>	<u>168,568</u>
NET CURRENT ASSETS			
		<u>317,565</u>	<u>168,568</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>317,565</u>	<u>168,568</u>
NET ASSETS			
		<u>317,565</u>	<u>168,568</u>
FUNDS			
	13		
Unrestricted funds		300,463	108,113
Restricted funds		17,102	60,455
		<u>317,565</u>	<u>168,568</u>
TOTAL FUNDS			
		<u>317,565</u>	<u>168,568</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 19th July 2022 and were signed on its behalf by:


 B Stedman - Trustee

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

2. DONATIONS AND LEGACIES

	2022	2021
	£	£
Donations	91,154	74,103
Legacies	338,776	-
Ring-fenced Donations - IORT	11,550	54,455
Ring-fenced Donations - R&D	11,102	6,000
	<u>452,582</u>	<u>134,558</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

3. OTHER TRADING ACTIVITIES				
			2022	2021
			£	£
Fundraising events			<u>14,532</u>	<u>-</u>
4. INCOME FROM CHARITABLE ACTIVITIES				
			2022	2021
	Activity		£	£
	Charitable activities			
Merchandising			<u>1,118</u>	<u>730</u>
5. RAISING FUNDS				
Raising donations and legacies				
			2022	2021
			£	£
Fundraising expenditure			<u>25,112</u>	<u>-</u>
6. CHARITABLE ACTIVITIES COSTS				
		Direct	Support	Totals
		Costs	costs (see	
		£	note 7)	
			£	£
Charitable activities				
		<u>286,575</u>	<u>7,548</u>	<u>294,123</u>
7. SUPPORT COSTS				
	Management	Finance	Governance	Totals
	£	£	costs	
			£	£
Charitable activities				
	<u>3,756</u>	<u>205</u>	<u>3,587</u>	<u>7,548</u>

Support costs, included in the above, are as follows:

Management

		2022	2021
		Charitable	Total
		activities	activities
		£	£
Computer costs		1,972	1,349
Training costs		1,384	-
Postage and stationery		269	1,987
Sundries		131	-
		<u>3,756</u>	<u>3,336</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

7. SUPPORT COSTS - continued
Finance

	2022 Charitable activities	2021 Total activities
	£	£
Bank charges	205	242
Governance costs		
	2022 Charitable activities	2021 Total activities
	£	£
Professional fee	450	-
Trustee meeting expenses	746	99
Donor meeting expenses	783	112
Accountancy	1,608	492
	<u>3,587</u>	<u>703</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2022 nor for the year ended 31 March 2021.

Trustees' expenses

During the year no trustees (2021: none) were reimbursed out of pocket expenses totalling £nil (2021: £nil).

9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	74,103	60,455	134,558
Charitable activities			
Charitable activities	730	-	730
Total	<u>74,833</u>	<u>60,455</u>	<u>135,288</u>
EXPENDITURE ON			
Charitable activities			
Charitable activities	185,099	-	185,099
NET INCOME/(EXPENDITURE)	<u>(110,266)</u>	<u>60,455</u>	<u>(49,811)</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued				
		Unrestricted fund £	Restricted funds £	Total funds £
RECONCILIATION OF FUNDS				
Total funds brought forward		218,379	-	218,379
TOTAL FUNDS CARRIED FORWARD		<u>108,113</u>	<u>60,455</u>	<u>168,568</u>
10. STOCKS			2022 £	2021 £
Stocks			<u>2,514</u>	<u>1,750</u>
11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR			2022 £	2021 £
Other creditors			<u>1,585</u>	<u>480</u>
12. ANALYSIS OF NET ASSETS BETWEEN FUNDS			2022 Total funds £	2021 Total funds £
	Unrestricted fund £	Restricted funds £		
Current assets	302,048	17,102	319,150	169,048
Current liabilities	(1,585)	-	(1,585)	(480)
	<u>300,463</u>	<u>17,102</u>	<u>317,565</u>	<u>168,568</u>
13. MOVEMENT IN FUNDS			Transfers between funds £	At 31.3.22 £
	At 1.4.21 £	Net movement in funds £		
Unrestricted funds				
General fund	108,113	337,448	(145,098)	300,463
Restricted funds				
IORT fund	54,455	(199,553)	145,098	-
R&D fund	6,000	11,102	-	17,102
	<u>60,455</u>	<u>(188,451)</u>	<u>145,098</u>	<u>17,102</u>
TOTAL FUNDS	<u>168,568</u>	<u>148,997</u>	<u>-</u>	<u>317,565</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

13. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	445,580	(108,132)	337,448
Restricted funds			
IORT fund	11,550	(211,103)	(199,553)
R&D fund	11,102	-	11,102
	<u>22,652</u>	<u>(211,103)</u>	<u>(188,451)</u>
TOTAL FUNDS	<u>468,232</u>	<u>(319,235)</u>	<u>148,997</u>

Comparatives for movement in funds

	At 1.4.20 £	Net movement in funds £	At 31.3.21 £
Unrestricted funds			
General fund	218,379	(110,266)	108,113
Restricted funds			
IORT fund	-	54,455	54,455
R&D fund	-	6,000	6,000
	<u>-</u>	<u>60,455</u>	<u>60,455</u>
TOTAL FUNDS	<u>218,379</u>	<u>(49,811)</u>	<u>168,568</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	74,833	(185,099)	(110,266)
Restricted funds			
IORT fund	54,455	-	54,455
R&D fund	6,000	-	6,000
	<u>60,455</u>	<u>-</u>	<u>60,455</u>
TOTAL FUNDS	<u>135,288</u>	<u>(185,099)</u>	<u>(49,811)</u>

IORT fund - Planets hold a contract to pay the hospital monthly instalments for the lease purchase of the IORT machine. Planets does not own it as it is gifted to the hospital. This lease was fully paid off during the financial year.

PLANETS CANCER CHARITY

England & Wales - Charity number 1175572

Accounts

Your Company Name and/or Letter Head

BUSINESS ADVISORS • CHARTERED ACCOUNTANTS • REGISTERED AUDITORS

Mrs Layla Stephen
113 Havant Road
Emsworth
Hampshire
PO10 7LG
PLANETS Cancer Charity

11 January 2022

Dear Layla,

Accounts for Period ended 31/03/2021

Please find attached final accounts for PLANETS Cancer Charity for the period ended 31/03/2021 [including filleted/abbreviated accounts if appropriate].

Please review the attached carefully and if you are happy that the accounts can be approved please print out a set of each of the attached documents, obtain appropriate signatures at the foot of each Balance Sheet [and Directors Report, if relevant] and return the signed documents to this office.

Please do not hesitate to contact us if you have any queries.

Yours sincerely,

Amelia Griffiths

PLANETS Cancer Charity

Charity No. 1175572

Company No. CEO11985

Trustees' Report and Unaudited Financial
Statements

For the year 1 April 2020 to 31 March 2021

PLANETS Cancer Charity
Contents

	Pages
Trustees' Annual Report	2 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Summary Income and Expenditure Account	7
Balance Sheet	8
Statement of Cash flows	9
Notes to the Accounts	10 to 16
Detailed Statement of Financial Activities	17 to 18

The trustees present their report with the financial statements of the charity for the year ended 31 March 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

REFERENCE AND ADMINISTRATIVE DETAILS

Company No. CEO11985

Charity No. 1175572

Principal Office

113 Havant Road
Emsworth
Hampshire
PO10 7LG

Registered Office

113 Havant Road
Emsworth
Hampshire
PO10 7LG

Directors and Trustees

The Directors of the charitable company are its Trustees for the purposes of charity law.

The following Directors and Trustees served during the year:

V. Caine

E. Dolan

R.J. Griffiths

A. Mirnezami

N.W. Pearce

B. Stedman

T. Underwood

R. Willrich

Key Management Personnel

Mrs Layla Stephen
Accountants

Anavrin Limited
113 Altwood Road
Maidenhead
Berkshire
SL6 4QD

Bankers
Lloyds Bank
25 Gresham Street
London EC2V 7HN

Independent Examiner

P Underwood, ACCA
Morris Crocker Chartered Accountants
Station House
North Street
Havant, PO9 1QU

OBJECTIVES AND ACTIVITIES

Planets helps patients with pancreatic, liver, colorectal, abdominal and neuroendocrine cancer.

Funding patient support groups, innovative treatments and research.

Establishing a network of patient support groups across the Wessex region.

Funding the introduction of intra operative radiotherapy (IORT) with the UK's first mobile electron beam radiotherapy machine, able to deliver radiotherapy to advanced cancers during surgery.

Funding a full-time pancreatic and neuroendocrine tumour researcher to work with the clinician scientists in Southampton's world leading cancer immunology research department.

ACHIEVEMENTS AND PERFORMANCE

We have seen the implementation of our intra-operative electron beam radiotherapy (IORT) program in Southampton delivering world-class, combined surgical and radiotherapy treatments to patients with advanced cancers from across our central South coast region.

We have recently broadened our charitable support base to include patients with forms of cancer involving other abdominal organs (including bowel, stomach and gullet cancer) as they have so much in common with the cancer patients that we are already helping and working with:

Patient support groups

Patient Conferences

Patient psychotherapy sessions

All of which have brought our local cancer community together.

In line with our Charitable goals all of our funds raised are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

FINANCIAL REVIEW

The Charity's financial position as at 31 March 2021 can be found in the Balance Sheet on page 8. As at 31 March 2021 the charity bank balance was £167,298. The charity generated income of £135,288 for the period from 1 April 2020 to 31 March 2021.

For 2020/21 the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover one year's governance, management, fundraising and administration, which in 2021/22 are budgeted to be £40,000. We aim to spend income within 24 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment (although the Charity holds no such obligation at present), we retain those sums in a designated fund until enough money is available to meet the full cost of the project.

The Trustees have assessed the specific uncertainties surrounding the Covid 19 pandemic and have adapted the strategy of the charity to this new environment. Even though the full impact remains difficult to quantify the Trustees acknowledge that there has been an impact on fundraising events for 2020/21 and have an expectation that there could be an impact on these events planned for 2022. The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements.

PLANS FOR FUTURE PERIODS

PLANETS need to raise a total of another £120,000 over the next 12 months to fund IORT (Intra-Operative Radiation Therapy). The cost of the IORT is £10K per month from Dec 2021.

In order to secure the future of this IORT machine through to the end of its working life (2030) we would need to raise an additional £250,000.

Our ongoing commitment to patient support requires £50,000 over the next five years.

We intend to fund the introduction of Nano-knife and HiPeC treatments for advanced cancers. Set up costs for these total £100,000.

We aim to raise another £250,000 over the next five years towards research into the immunology and tumour micro-environment of pancreatic and neuroendocrine cancers.

A NET dietitian has been jointly funded with the RobertWhite Trust to help patients across the Wessex NET group area, including attendance at the weekly NET MDT as well as at the monthly NET clinics in Dorchester, Poole, Bournemouth, Southampton and Portsmouth. The role is also designed to include education of patients and other members of the clinical service around the region about dietary management of NET patients. (Funding started in May 2021 at a cost of £5k per month).

STRUCTURE, GOVERNANCE AND MANAGEMENT

Planets is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution.

The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason.

Signed on behalf of the board

N.W. Pearce

Trustee

20 January 2022

Independent Examiner's Report to the trustees of PLANETS Cancer Charity

I report to the charity trustees on my examination of the accounts of PLANETS Cancer Charity for the year ended 31 March 2021 which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet, the Statement of Cash Flows and the related notes.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011.

Having satisfied myself that the accounts of the charity are not required to be audited under Part 16 section 145 of the 2011 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I can confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that:

- accounting records were not kept in accordance with section 130 of the 2011 Act ; or
- the accounts do not accord with those records; or
- the accounts do not comply with the accounting requirements under section 130 of the 2011 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the accounts have not been prepared in accordance with the Charities SORP (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

P Underwood
ACCA
Morris Crocker Chartered Accountants
Station House
North Street
Havant
PO9 1QU
Date:

PLANETS Cancer Charity
Statement of Financial Activities
For the year ended 31 March 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income and endowments from:					
Donations and legacies	4	74,103	60,455	134,558	156,049
Charitable activities	5	730	-	730	20,798
Total		74,833	60,455	135,288	176,847
Expenditure on:					
Raising funds	6	-	-	-	239
Charitable activities	7	3,619	-	3,619	19,580
Other	8	181,480	-	181,480	56,301
Total		185,099	-	185,099	76,120
Net gains on investments		-	-	-	-
Net (expenditure)/income		(110,266)	60,455	(49,811)	100,727
Transfers between funds		-	-	-	-
Net (expenditure)/income before other gains/(losses)		(110,266)	60,455	(49,811)	100,727
Other gains and losses					
Net movement in funds		(110,266)	60,455	(49,811)	100,727
Reconciliation of funds:					
Total funds brought forward		218,379	-	218,379	117,652
Total funds carried forward		<u>108,113</u>	<u>60,455</u>	<u>168,568</u>	<u>218,379</u>

PLANETS Cancer Charity
Summary Income and Expenditure Account
For the year ended 31 March 2021

	2021 £	2020 £
Income	135,288	176,847
Gross income for the year	<u>135,288</u>	<u>176,847</u>
Expenditure	185,099	76,120
Total expenditure for the year	<u>185,099</u>	<u>76,120</u>
Net (expenditure)/income before tax for the year	(49,811)	100,727
Net (expenditure)/income for the year	<u>(49,811)</u>	<u>100,727</u>

PLANETS Cancer Charity

Balance Sheet

At 31 March 2021

Company No. CEO11985	Notes	2021 £	2020 £
Current assets			
Stocks	10	1,750	1,750
Debtors	11	-	1,480
Cash at bank and in hand		167,298	215,629
		<u>169,048</u>	<u>218,859</u>
Creditors: Amount falling due within one year	12	(480)	(480)
Net current assets		168,568	218,379
Total assets less current liabilities		168,568	218,379
Net assets excluding pension asset or liability		168,568	218,379
Total net assets		<u>168,568</u>	<u>218,379</u>
The funds of the charity			
Restricted funds	13		
Restricted income funds		60,455	-
		<u>60,455</u>	<u>-</u>
Unrestricted funds	13		
General funds		108,113	218,379
		<u>108,113</u>	<u>218,379</u>
Reserves	13		
Total funds		<u>168,568</u>	<u>218,379</u>

The financial statements were approved by the board of Trustees and authorised for issue on 20 January 2022

And signed on its behalf by:

N.W. Pearce
Trustee
20 January 2022

PLANETS Cancer Charity
Statement of Cash flows

For the year ended 31 March 2021

	2021 £	2020 £
Cash flows from operating activities		
Net (expenditure)/income per Statement of Financial Activities	(49,811)	100,727
Adjustments for:		
Increase in stocks	-	(1,010)
Decrease/(Increase) in trade and other receivables	1,480	(1,276)
Decrease in trade and other payables	-	(1,755)
Net cash (used in)/provided by operating activities	<u>(48,331)</u>	<u>96,686</u>
Net cash from investing activities	<u>-</u>	<u>-</u>
Net cash from financing activities	<u>-</u>	<u>-</u>
Net (decrease)/increase in cash and cash equivalents	(48,331)	96,686
Cash and cash equivalents at the beginning of the year	215,629	118,943
Cash and cash equivalents at the end of the year	<u>167,298</u>	<u>215,629</u>
Components of cash and cash equivalents		
Cash and bank balances	167,298	215,629
	<u>167,298</u>	<u>215,629</u>

For the year ended 31 March 2021

1 Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Change in basis of accounting or to previous accounts

There has been no change to the accounting policies (valuation rules and method of accounting) since last year and no changes have been made to accounts for previous years.

Fund accounting

Unrestricted funds These are available for use at the discretion of the trustees in furtherance of the general objects of the charity.

Designated funds These are unrestricted funds earmarked by the trustees for particular purposes.

Revaluation funds These are unrestricted funds which include a revaluation reserve representing the restatement of investment assets at their market values.

Restricted funds These are available for use subject to restrictions imposed by the donor or through terms of an appeal.

Income

Recognition of income Income is included in the Statement of Financial Activities (SoFA) when the charity becomes entitled to, and virtually certain to receive, the income and the amount of the income can be measured with sufficient reliability.

Income with related expenditure Where income has related expenditure the income and related expenditure is reported gross in the SoFA.

Donations and legacies Voluntary income received by way of grants, donations and gifts is included in the the SoFA when receivable and only when the Charity has unconditional entitlement to the income.

Tax reclaims on donations and gifts Income from tax reclaims is included in the SoFA at the same time as the gift/donation to which it relates.

Donated services and facilities These are only included in income (with an equivalent amount in expenditure) where the benefit to the Charity is reasonably quantifiable, measurable and material.

Volunteer help The value of any volunteer help received is not included in the accounts.

Investment income This is included in the accounts when receivable.

Gains/(losses) on revaluation of fixed assets This includes any gain or loss resulting from revaluing investments to market value at the end of the year.

Gains/(losses) on investment assets This includes any gain or loss on the sale of investments.

Expenditure

Recognition of expenditure Expenditure is recognised on an accruals basis. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Expenditure on raising funds These comprise the costs associated with attracting voluntary income, fundraising trading costs and investment management costs.

Expenditure on charitable activities These comprise the costs incurred by the Charity in the delivery of its activities and services in the furtherance of its objects, including the making of grants and governance costs.

Grants payable All grant expenditure is accounted for on an actual paid basis plus an accrual for grants that have been approved by the trustees at the end of the year but not yet paid.

Governance costs These include those costs associated with meeting the constitutional and statutory requirements of the Charity, including any audit/independent examination fees, costs linked to the strategic management of the Charity, together with a share of other administration costs.

Other expenditure These are support costs not allocated to a particular activity.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Stocks

Stock is included at the lower of cost or net realisable value. Donated items of stock are recognised at fair value which is the amount the charity would have been willing to pay for the items on the open market.

Trade and other debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the statement of financial position, bank overdrafts are shown within borrowings or current liabilities. In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the company's cash management.

Trade and other creditors

Short term creditors are measured at the transaction price. Other creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

2 Company status

The company is a Foundation Charitable Incorporated Organisation.

3 Statement of Financial Activities - prior year

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Income and endowments from:			
Donations and legacies	149,049	7,000	156,049
Charitable activities	20,798	-	20,798
Total	<u>169,847</u>	<u>7,000</u>	<u>176,847</u>
Expenditure on:			
Raising funds	239	-	239
Charitable activities	19,580	-	19,580
Other	56,301	-	56,301
Total	<u>76,120</u>	<u>-</u>	<u>76,120</u>
Net income	<u>93,727</u>	<u>7,000</u>	<u>100,727</u>
Net income before other gains/(losses)	93,727	7,000	100,727
Other gains and losses:			
Net movement in funds	<u>93,727</u>	<u>7,000</u>	<u>100,727</u>
Reconciliation of funds:			
Total funds brought forward	117,652	-	117,652
Total funds carried forward	<u><u>211,379</u></u>	<u><u>7,000</u></u>	<u><u>218,379</u></u>

4 Income from donations and legacies

	Unrestricted £	Restricted £	Total 2021 £	Total 2020 £
Donations	74,103	-	74,103	129,049
Legacies	-	-	-	20,000
Ring-fenced Donations - IORT	-	54,455	54,455	7,000
Ring Fenced Donations - R&D	-	6,000	6,000	-
	<u>74,103</u>	<u>60,455</u>	<u>134,558</u>	<u>156,049</u>

5 Income from charitable activities

	Unrestricted £	Total 2021 £	Total 2020 £
Event	-	-	20,290
Merchandising	730	730	508
	<u>730</u>	<u>730</u>	<u>20,798</u>

6 Expenditure on raising funds

	Total 2021 £	Total 2020 £
<i>Costs of generating voluntary income</i>		
Donations	-	239
	<u>-</u>	<u>239</u>

7 Expenditure on charitable activities

	Unrestricted £	Total 2021 £	Total 2020 £
<i>Expenditure on charitable activities</i>			
Event	(199)	(199)	16,444
Merchandising	453	453	343
Advertising and Promotions	3,365	3,365	2,793
<i>Governance costs</i>			
	<u>3,619</u>	<u>3,619</u>	<u>19,580</u>

8 Other expenditure

	Unrestricted £	Total 2021 £	Total 2020 £
Donor meeting expenses	112	112	341
Patient support group	-	-	4,995
Trustee meeting expenses	99	99	215
Machinery purchase for hospital	149,996	149,996	20,000
Motor and travel costs	-	-	219
Premises costs	1,230	1,230	1,025
General administrative costs	3,578	3,578	3,791
Legal and professional costs	26,465	26,465	25,715
	<u>181,480</u>	<u>181,480</u>	<u>56,301</u>

9 Staff costs

No employee received emoluments in excess of £60,000.

10 Stocks

	2021	2020
	£	£
Raw materials and consumables	1,750	1,750
	<u>1,750</u>	<u>1,750</u>

Carrying value analysed by activities

	2021	2020
	£	£
Merchandising	1,750	1,750
	<u>1,750</u>	<u>1,750</u>

11 Debtors

	2021	2020
	£	£
Trade debtors	-	1,480
	<u>-</u>	<u>1,480</u>

12 Creditors:

amounts falling due within one year

	2021	2020
	£	£
Accruals and deferred income	480	480
	<u>480</u>	<u>480</u>

13 Movement in funds

	At 1 April 2020	Incoming resources (including other gains/losses) £	Resources expended £	At 31 March 2021 £
Restricted funds:				
Restricted income funds:				
Ring Fenced Donations - IORT Machine	-	54,455	-	54,455
Ring Fenced Donations - R&D	-	6,000	-	6,000
<i>Total</i>	<u>-</u>	<u>60,455</u>	<u>-</u>	<u>60,455</u>
Unrestricted funds:				
General funds	218,379	74,833	(185,099)	108,113
Revaluation Reserves:				
Total funds	<u>218,379</u>	<u>135,288</u>	<u>(185,099)</u>	<u>168,568</u>

Purposes and restrictions in relation to the funds:

Restricted funds:

Ring Fenced Donations - IORT Machine PLANETS hold a contract to pay the hospital monthly instalments for the lease purchase of the IORT machine- Planets does not own it as it is gifted to the hospital.

Ring Fenced Donations - R&D Research and Development donations for research conducted by an individual.

14 Analysis of net assets between funds

	Unrestricted funds £	Total £
Net current assets	168,568	168,568
	<u>168,568</u>	<u>168,568</u>

Total net current assets are made up of £108,113 of unrestricted funds and £60,455 of restricted funds.

15 Reconciliation of net debt

	At 1 April 2020 £	Cash flows £	At 31 March 2021 £
Cash and cash equivalents	215,629	(48,331)	167,298
	<u>215,629</u>	<u>(48,331)</u>	<u>167,298</u>
Net debt	<u>215,629</u>	<u>(48,331)</u>	<u>167,298</u>

16 Related party disclosures

Controlling party

The company is a Foundation Charitable Incorporated Organisation and has no share capital; thus no single party controls the company.

PLANETS Cancer Charity
Detailed Statement of Financial Activities

For the year ended 31 March 2021

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income and endowments from:				
Donations and legacies				
Donations	74,103	-	74,103	129,049
Legacies	-	-	-	20,000
Ring-fenced Donations - IORT	-	54,455	54,455	7,000
Ring Fenced Donations - R&D	-	6,000	6,000	-
	<u>74,103</u>	<u>60,455</u>	<u>134,558</u>	<u>156,049</u>
Charitable activities				
Event	-	-	-	20,290
Merchandising	730	-	730	508
	<u>730</u>	<u>-</u>	<u>730</u>	<u>20,798</u>
Total income and endowments	74,833	60,455	135,288	176,847
Expenditure on:				
Costs of generating donations and legacies				
Donations	-	-	-	239
	<u>-</u>	<u>-</u>	<u>-</u>	<u>239</u>
Total of expenditure on raising funds	-	-	-	239
Charitable activities				
Event	(199)	-	(199)	16,444
Merchandising	453	-	453	343
Advertising and Promotions	3,365	-	3,365	2,793
	<u>3,619</u>	<u>-</u>	<u>3,619</u>	<u>19,580</u>
Total of expenditure on charitable activities	3,619	-	3,619	19,580
Other expenditure				
Donor meeting expenses	112	-	112	341
Patient support group	-	-	-	4,995
Trustee meeting expenses	99	-	99	215
Machinery purchase for hospital	149,996	-	149,996	20,000
	<u>150,207</u>	<u>-</u>	<u>150,207</u>	<u>25,551</u>
Travel and subsistence	-	-	-	219
	<u>-</u>	<u>-</u>	<u>-</u>	<u>219</u>
Premises costs				
Rent	650	-	650	450
Premises insurances	580	-	580	575
	<u>1,230</u>	<u>-</u>	<u>1,230</u>	<u>1,025</u>

PLANETS Cancer Charity
Detailed Statement of Financial Activities

General administrative costs, including depreciation and amortisation				
Bank charges	242	-	242	101
Software, IT support and related costs	1,349	-	1,349	2,113
Stationery and printing	1,987	-	1,987	385
Sundry expenses	-	-	-	1,192
	<u>3,578</u>	<u>-</u>	<u>3,578</u>	<u>3,791</u>
Legal and professional costs				
Accountancy and bookkeeping	492	-	492	480
Consultancy fees	5,995	-	5,995	-
Management charges	19,978	-	19,978	25,035
Other legal and professional costs	-	-	-	200
	<u>26,465</u>	<u>-</u>	<u>26,465</u>	<u>25,715</u>
Total of expenditure of other costs	<u>181,480</u>	<u>-</u>	<u>181,480</u>	<u>56,301</u>
Total expenditure	185,099	-	185,099	76,120
Net gains on investments	-	-	-	-
Net (expenditure)/income	<u>(110,266)</u>	<u>60,455</u>	<u>(49,811)</u>	<u>100,727</u>
Net (expenditure)/income before other gains/(losses)	<u>(110,266)</u>	<u>60,455</u>	<u>(49,811)</u>	<u>100,727</u>
Other Gains	-	-	-	-
Net movement in funds	<u>(110,266)</u>	<u>60,455</u>	<u>(49,811)</u>	<u>100,727</u>
Reconciliation of funds:				
Total funds brought forward	218,379	-	218,379	117,652
Total funds carried forward	<u>108,113</u>	<u>60,455</u>	<u>168,568</u>	<u>218,379</u>